Reduced platelet count in mice protects against glucose intolerance and beta cell loss during a long-term high-fat diet - Scorecard - MDSpire

Reduced platelet count in mice protects against glucose intolerance and beta cell loss during a long-term high-fat diet

  • By

  • Niklas Burkhard

  • Johannes Hoch

  • Shanshan Zhang

  • Muataz Ali Hamad

  • Nicolas Schommer

  • Carolin Mogler

  • Daniela Stallmann

  • Pierre Mangin

  • Krystin Krauel

  • Daniel Duerschmied

  • Nancy Schanze

  • July 1, 2026

  • 0 min

Share

Clinical Scorecard: Decreased Platelet Levels in Mice Provide Protection Against Glucose Intolerance and Beta Cell Degeneration Induced by Prolonged High-Fat Diet

At a Glance

CategoryDetail
ConditionType 2 Diabetes (T2D)
Key MechanismsPlatelets interact with pancreatic beta cells, influencing insulin secretion and glucose metabolism.
Target PopulationMice models of obesity-related T2D.
Care SettingExperimental animal research.

Key Highlights

  • Thrombocytopenia in MPL-/- mice improved glucose tolerance compared to wild type mice on a high-fat diet.
  • MPL-/- mice exhibited higher insulin levels despite increased insulin resistance.
  • Platelet count reduction was associated with preservation of pancreatic beta cells.

Guideline-Based Recommendations

Diagnosis

  • Monitor glucose tolerance and insulin levels in obesity models.

Management

  • Investigate the role of platelets in insulin secretion and beta cell health.

Monitoring & Follow-up

  • Assess metabolic parameters in animal models of T2D.

Risks

  • Consider the implications of chronic thrombocytopenia on overall metabolic health.

Patient & Prescribing Data

Not applicable; study conducted in mice.

Chronic thrombocytopenia may protect against obesity-induced beta cell degeneration.

Clinical Best Practices

  • Utilize animal models to explore the pathophysiology of T2D.
  • Consider the inflammatory role of platelets in metabolic diseases.

Related Resources & Content

Original Source(s)

Reduced platelet count in mice protects against glucose intolerance and beta cell loss during a long-term high-fat diet

  • by Niklas Burkhard, Johannes Hoch, Shanshan Zhang, Muataz Ali Hamad, Nicolas Schommer, Carolin Mogler, Daniela Stallmann, Pierre Mangin, Krystin Krauel, Daniel Duerschmied, Nancy Schanze

  • July 1, 2026

Related Content

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.

The mysterious case of Eli Lilly’s obesity drug

Preoperative Weight Loss: Helpful, Harmful or Irrelevant?